Compare SHC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | MIRM |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.7B |
| IPO Year | 2020 | 2019 |
| Metric | SHC | MIRM |
|---|---|---|
| Price | $15.35 | $93.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $20.67 | ★ $115.33 |
| AVG Volume (30 Days) | ★ 2.6M | 816.3K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.75 | ★ 74.59 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $1,163,617,000.00 | $19,138,000.00 |
| Revenue This Year | $7.51 | $26.22 |
| Revenue Next Year | $6.00 | $22.04 |
| P/E Ratio | $56.91 | ★ N/A |
| Revenue Growth | ★ 5.74 | N/A |
| 52 Week Low | $10.17 | $37.83 |
| 52 Week High | $19.85 | $109.28 |
| Indicator | SHC | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 50.50 |
| Support Level | $15.19 | $85.35 |
| Resistance Level | $16.55 | $96.65 |
| Average True Range (ATR) | 0.43 | 3.79 |
| MACD | 0.30 | 0.88 |
| Stochastic Oscillator | 95.94 | 60.83 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.